Payment overview · 2025
General Payments
$191.49
11 reported records · 9 companies
Healthcare provider profile · identity verified
Kari Tatum
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · COMMERCE, GA · NPI 1083354690
Verified facts
What the public records show
CMS Open Payments records show Kari Tatum received $191.49 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.74 | 24.9% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $21.66 | 11.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.39 | 11.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.32 | 10.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.61 | 9.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.30 | 8.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.91 | 8.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.53 | 8.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.03 | 7.8% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $191.49 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $47.74 | 2 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | SANOFI PASTEUR INC. | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.03 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 198 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 182 | 68 |
| Lisinopril | Lisinopril | 161 | 67 |
| Gabapentin | Gabapentin | 125 | 53 |
| Losartan Potassium | Losartan Potassium | 122 | 45 |
| Metformin Hcl | Metformin Hcl | 111 | 39 |
| Atorvastatin Calcium | Atorvastatin Calcium | 109 | 47 |
| Meloxicam | Meloxicam | 107 | 45 |
| Omeprazole | Omeprazole | 104 | 43 |
| Sertraline Hcl | Sertraline Hcl | 92 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 31 |
| Tramadol Hcl | Tramadol Hcl | 85 | 26 |
| Prednisone | Prednisone | 81 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 79 | 29 |
| Azithromycin | Azithromycin | 75 | 59 |
| Potassium Chloride | Potassium Chloride | 71 | 28 |
| Furosemide | Furosemide | 63 | 31 |
| Atenolol | Atenolol | 62 | 23 |
| Glipizide | Glipizide | 56 | 24 |
| Trazodone Hcl | Trazodone Hcl | 55 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 24 |
| Famotidine | Famotidine | 51 | 23 |
| Alendronate Sodium | Alendronate Sodium | 50 | 22 |
| Lovastatin | Lovastatin | 48 | 19 |
| Allopurinol | Allopurinol | 45 | 21 |
| Simvastatin | Simvastatin | 45 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 18 |
| Cefuroxime | Cefuroxime Axetil | 42 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 13 |
| Cephalexin | Cephalexin | 39 | 35 |
| Montelukast Sodium | Montelukast Sodium | 39 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 36 | 15 |
| Buspirone Hcl | Buspirone Hcl | 35 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 35 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 21 |
| Amoxicillin | Amoxicillin | 31 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 30 | 15 |
| Ozempic | Semaglutide | 29 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | 13 |
| Eliquis | Apixaban | 25 | 11 |
| Meclizine Hcl | Meclizine Hcl | 25 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Celecoxib | Celecoxib | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 17 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $191.49 · 11 records | AstraZeneca Pharmaceuticals LP | BEYFORTUS, CAPLYTA, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, MOUNJARO, VAXELIS, VIBERZI, VOQUEZNA, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error